<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778518</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-ARX201-701</org_study_id>
    <secondary_id>EudraCT: 2007-001746-40</secondary_id>
    <nct_id>NCT00778518</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).</brief_title>
  <official_title>Phase IIb Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ambrx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to find the optimal dose of Growth Hormone Replacement in young adult patients
      suffering from childhood onset growth hormone deficiency (GHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety, tolerability and
      pharmacodynamic response of three different ARX201 doses (PEG-ahGH) when administered
      repeatedly to young adult patients with childhood onset growth hormone deficiency (GHD).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temporal profiling of circulating IGF-1 levels.</measure>
    <time_frame>3 period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition measurements at start of study and end of study</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARX201</intervention_name>
    <description>Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARX201</intervention_name>
    <description>Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARX201</intervention_name>
    <description>Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-30 years old

          -  GHD of childhood onset

          -  completed growth

          -  IGF-1 &lt;=2SDS

          -  rhGH treatment naive

          -  hGH levels below cut-off

        Exclusion Criteria:

          -  History of malignancy or intracranial tumors

          -  ECG abnormality

          -  ICH

          -  hepatic dysfunction

          -  renal impairment

          -  major medical conditions

          -  inadequate T4

          -  positive for HBV, HCV, or HIV

          -  alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihaly Juhasz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Accelsiors CRO &amp; Consultancy Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelsiors CRO and Consultancy Services</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>October 9, 2009</last_update_submitted>
  <last_update_submitted_qc>October 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Douglas W. Axelrod, MD, PhD, Sr. Vice President</name_title>
    <organization>Clinical Research and Development, Ambrx, Inc.</organization>
  </responsible_party>
  <keyword>growth hormone</keyword>
  <keyword>growth hormone deficiency</keyword>
  <keyword>GHD</keyword>
  <keyword>PEG</keyword>
  <keyword>pegylated</keyword>
  <keyword>IGF-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

